Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2008-01-22
2008-01-22
McGarry, Sean (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S023000, C435S024000, C435S024000
Reexamination Certificate
active
07320964
ABSTRACT:
The invention relates to decoy oligonucleotides and antisense oligonucleotides comprising a nucleic acid sequence according to SEQ ID NO: 1 to 43, in addition to the use of said nucleotides as medicaments.
REFERENCES:
patent: 2004/0048820 (2004-03-01), Hecker et al.
patent: WO 95/08001 (1995-03-01), None
patent: WO 95/11687 (1995-05-01), None
patent: WO 02/29044 (2002-04-01), None
Huang et al., “Role of Janus kinase (JAK)/signal transducters and activators of transcription (STAT) cascade in advanced glycation end-product-induced cellular mitogenesis in NRK-49F cells,”Biochem. J., 342:231-238, 1999.
Krzesz et al., “Cytokine-inducible CD40 gene expression in vascular smooth muscle cells is mediated by nuclear factor κB and signal transducer and activato of transcription-1,”FEBS Lett., 453:191-196, 1999.
Lauth et al., “Transcriptional control of deformation-induced preproendothelin-1 gene expression in endothelial cells ,”J. Mol. Med., 78(8):441-450, 2000.
Lee and Beneveniste, “Stat1 α expression is involved in 1FN-γ induction of the class II transactivator and class II MHC genes,”J. Immunol., 157:1559-1568, 1996.
Mann and Dzau, “Therapeutic applications of transcription factor decoy oligonucleotides,”J. Clin. Invest., 106(9):1071-1075, 2000.
Morishita et al., “A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo,”Proc. Natl. Acad. Sci., USA, 92(13):5855-5859, 1995.
Morishita et al., “Gene therapy in vascular medicine: recent advances and future perspectives,”Pharmacology and Therapeutics, 91:105-114, 2001.
Ohmori et al., “Synergy between interferon-gamma and tumor necrosis factor-alpha in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor kappaB ,”J. Biol. Chem., 272(23):14899-14907, 1997.
Schieffer et al., “Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction ,”Circ. Res., 87(12):1195-1201, 2000.
Stephanou et al., “Ishemia-induced STAT-1 expression and activation play a critical role in cardiomyocyte apoptosis,”J. Biol. Chem., 275(14):10002-10008, 2000.
Varga et al., “Antisense strategies: functions and applications in immunology,”Immunology Letters, 69:217-224, 1999.
Hecker Markus
Wagner Andreas H.
Avontec GmbH
Fulbright & Jaworski L.L.P.
McGarry Sean
LandOfFree
Modulation of expression of STAT-1 dependent genes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of expression of STAT-1 dependent genes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of expression of STAT-1 dependent genes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2773096